Article PDF first page preview

First page of Plasma Levels of Transient Receptor Potential Vanilloid 1 as a Novel Biomarker for Acute Myocardial Infarction

Objective: This study aims to investigate the diagnostic significance of plasma transient receptor potential vanilloid 1 (TRPV1) levels in patients with acute myocardial infarction (AMI) and to evaluate its prognostic value. Methods: A total of 152 patients diagnosed with AMI at Zhongda Hospital between May 2023 and March 2024, forming the AMI group, along with 62 non-AMI patients as the control group. Plasma TRPV1 levels were measured using enzyme-linked immunosorbent assay (ELISA) upon admission. All patients with AMI were followed up for six months. Results: Plasma TRPV1 levels were significantly higher in the AMI group compared to the control group (p <0.05). Pearson correlation analysis demonstrated that TRPV1 levels positively correlated with diabetes, lactate dehydrogenase (LDH), white blood cell count, creatine kinase, blood urea nitrogen (BUN), serum creatinine (Scr), glycated hemoglobin (HbA1c), brain natriuretic peptide (BNP), cardiac troponin I (cTnI), Gensini scores, and the number of affected vessels, while showing a negative correlation with hemoglobin and left ventricular ejection fraction (LVEF). Multiple linear regression analysis identified LDH, Scr, and HbA1c as independent factors influencing TRPV1 levels. Receiver operating characteristic (ROC) curve analysis demonstrated a significant diagnostic value of TRPV1 for AMI (p <0.001). Furthermore, Cox regression analysis revealed that elevated TRPV1 levels were significantly associated with the occurrence of major adverse cardiac events (MACE) within six months (p <0.001). Conclusion: Plasma TRPV1 is a promising biomarker for the diagnosis of AMI, with potential links to renal function and glycemic control. Additionally, TRPV1 holds prognostic value for predicting MACE within six months following AMI.

Journal Section:
CAD and AMI
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.